La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

KORU Medical Systems Gestion

Gestion contrôle des critères 4/4

Le PDG KORU Medical Systems' est Linda Tharby, nommé en Apr2021, a un mandat de 3.33 ans. La rémunération annuelle totale est $ 713.37K, composée du salaire de 78.9% et des bonus 21.1%, y compris les actions et options de la société. détient directement 3.97% des actions de la société, d'une valeur de $ 4.20M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 3.3 ans.

Informations clés

Linda Tharby

Directeur général

US$713.4k

Rémunération totale

Pourcentage du salaire du PDG	78.9%
Durée du mandat du directeur général	3.3yrs
Propriété du PDG	4.0%
Durée moyenne d'occupation des postes de direction	2.5yrs
Durée moyenne du mandat des membres du conseil d'administration	3.3yrs

Mises à jour récentes de la gestion

Recent updates

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

Jul 14

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Aug 14

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Jan 27

KORU Medical Systems: A Razor & Razor Blade Story

Jan 11

Is Repro Med Systems, Inc. (NASDAQ:KRMD) Trading At A 50% Discount?

Dec 29

Have Insiders Been Buying Repro Med Systems, Inc. (NASDAQ:KRMD) Shares This Year?

Dec 03

The Independent Chairman of the Board of Repro Med Systems, Inc. (NASDAQ:KRMD), R. Fletcher, Just Bought 77% More Shares

Dec 03

Analyse de la rémunération des PDG

Comment la rémunération de Linda Tharby a-t-elle évolué par rapport aux bénéfices de KORU Medical Systems?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$713k	US$563k	-US$14m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$1m	US$550k	-US$9m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$7m	US$398k	-US$5m

Rémunération vs marché: La rémunération totale de Linda ($USD 713.37K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Linda a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Linda Tharby (56 yo)

3.3yrs

Titularisation

US$713,369

Compensation

Ms. Linda M. Tharby serves as President and Chief Executive Officer at KORU Medical Systems, Inc. (formerly known as Repro Med Systems, Inc.) since April 12, 2021 and serves as its Director since May 06, 2...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Linda Tharby	President	3.3yrs	US$713.37k	3.97% $ 4.3m
Thomas Adams	CFO, Secretary & Treasurer	less than a year	US$555.40k	0.22% $ 234.0k
Brian Case	Chief Technology Officer	2.3yrs	US$371.16k	0.26% $ 277.9k
Kenneth Miller	Chief Commercial Officer	less than a year	US$717.22k	pas de données
Christopher Pazdan	Chief Operating Officer	2.6yrs	pas de données	0.050% $ 54.0k
Rob Cannon	Vice President of Sales	3.6yrs	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de KRMD est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Linda Tharby	President	2.3yrs	US$713.37k	3.97% $ 4.3m
Edward Wholihan	Director	less than a year	US$28.10k	0.040% $ 42.9k
R. Fletcher	Independent Chairman of the Board	5.3yrs	US$140.00k	0.40% $ 427.4k
Robert Cascella	Independent Director	2.3yrs	US$125.00k	0.14% $ 153.3k
Joseph Manko	Lead Independent Director	8.5yrs	US$121.50k	0.36% $ 386.7k
Shahriar Matin	Independent Director	3.3yrs	US$110.00k	0.15% $ 159.5k
Donna French	Independent Director	3.3yrs	US$110.00k	0.14% $ 153.3k

3.3yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de KRMD sont considérés comme expérimentés (ancienneté moyenne 3.3 ans).

KORU Medical Systems Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

KORU Medical Systems, Inc Announces Executive Changes

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

High number of new directors

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

Recent updates

Consensus estimates of losses per share improve by 20%

New minor risk - Market cap size

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

KORU Medical Systems, Inc Announces Executive Changes

KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024

KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan

KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic Drug

Consensus EPS estimates fall by 15%

KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems, Inc. Reaffirmes Financial Guidance for the Full Year of 2024

KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024

KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic

KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Consensus EPS estimates upgraded to US$0.18 loss, revenue downgraded

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

New minor risk - Market cap size

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes

KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023

High number of new directors

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023

Price target decreased by 10% to US$4.33

KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled Syringes

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

KORU Medical Systems, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$4.83

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KORU Medical Revised Revenue Guidance for the Full Year of 2022

KORU Medical Systems, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

KORU Medical Systems, Inc. Revises Earnings Guidance for the Full Year 2022

KORU Medical Systems, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems Revises Earnings Guidance for the Year 2022

Price target decreased to US$4.67

Repro Med Systems, Inc. to Report Q1, 2022 Results on May 04, 2022

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Consensus forecasts updated

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Repro Med Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

Third quarter 2021 earnings released: US$0.025 loss per share (vs US$0.006 profit in 3Q 2020)

Price target decreased to US$4.67

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Second quarter 2021 earnings released: US$0.025 loss per share (vs US$0.027 loss in 2Q 2020)

Consensus forecasts updated

Consensus EPS estimates fall to -US$0.087

Repro Med Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000 Growth Index

Independent Chairman of the Board recently bought US$108k worth of stock

First quarter 2021 earnings released: US$0.029 loss per share (vs US$0.011 profit in 1Q 2020)